A Phase 2 interventional study of NT-0796 and Placebo in Obesity and Type 2 Diabetes, sponsored by Rezera (formerly NodThera Limited). Completed at 11 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Rezera (formerly NodThera Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes over a 6 months treatment period.
Potential participants will be screened within 28 days prior to baseline (Day 1), and eligible participants will be randomized 1:1:1 within each strata (T2DM or non-T2DM) to either NT-0796 twice daily (BID), NT-0796 once daily (QD) or placebo (BID). Study drug will be administered orally. Following 24 weeks of active treatment, participants will enter a 4-week safety follow-up before being discharged from the study. The primary endpoint of the study will be percentage weight change from baseline, the key-secondary endpoint will be change in HbA1c from baseline in the T2DM stratum, while secondary endpoints include DEXA scans, a variety of other relevant biometric measures as well as biomarkers. Pharmacokinetic, safety and tolerability as well as suicidality will also be assessed.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 176 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Rezera (formerly NodThera Limited) is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive study medication twice daily orally for up to 24 weeks, containing NT-0796 twice daily
Drug: NT-0796
Participants will receive study medication twice daily orally for up to 24 weeks, containing NT-0796 once daily, with once daily placebo
Drug: NT-0796 · Drug: Placebo
Participants will receive placebo twice daily orally for up to 24 weeks
Drug: Placebo
Orally administered capsules
Orally administered capsules
Ratio Change in hsCRP in participants with obesity and without T2DM hsCRP
Time frame: Baseline to Week 24
Change in body weight in participants with obesity with and without T2DM
Time frame: Baseline to Week 24
HbA1c in participants with T2DM
Time frame: Baseline to Week 24
Change in body weight in participants with obesity with and without T2DM
Time frame: Baseline to week 4, 8, 12, 16 and 20
Change in waist circumference in participants with obesity with and without T2DM
Time frame: Baseline to week 4, 8, 12, 16, 20 and 24
Change in waist/height ratio in participants with obesity with and without T2DM
Time frame: Baseline to week 4, 8, 12, 16, 20 and 24
Incidence of body weight loss ≥5% in participants with obesity with and without T2DM
Time frame: Baseline to Week 24
Incidence of body weight loss ≥10% in participants with obesity with and without T2DM
Time frame: Baseline to Week 24
Incidence of body weight loss ≥15% in participants with obesity with and without T2DM
Time frame: Baseline to Week 24
Change in metabolic biomarker in participants with and without T2DM
Time frame: Baseline to Week 24
Ratio change from baseline in hsCRP
Time frame: Weeks 4, 8, 12, 16, and 20
Time-averaged ratio change from baseline in hsCRP
Time frame: Between weeks 4 and 24.
Time-to- achievement of hsCRP < 2mg/L in the subset of subjects > 2mg/L at baseline
Time frame: Baseline to Week 24
Ratio change from baseline in fibrinogen
Time frame: Weeks 4, 8, 12, 16, 20 and 24.
Change in lean mass as measured by Dual-energy Xray absorptiometry (DEXA) in participants with obesity with and without T2DM
Time frame: Baseline to Week 24
Change in bone mineral density as measured by Dual-energy Xray absorptiometry (DEXA) in participants with obesity with and without T2DM
Time frame: Baseline to Week 24
Incidence of adverse events in participants with obesity with and without T2DM
Time frame: Baseline to Week 28
Pharmacokinetics (PK); Area Under the Concentration vs. Time curve of NT0796 in participants with obesity with and without T2DM
Time frame: Baseline to Week 24
PK; Maximum Plasma Concentration (Cmax) of NT0796 in participants with obesity with and without T2DM
Time frame: Baseline to Week 24
Ran from May 2025 to primary completion in May 2026, 12 months.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 12 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruvonoflast
Rezera (formerly NodThera Limited)